| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Military Personnel | 19 | 2022 | 84 | 2.680 |
Why?
|
| Anti-Infective Agents | 5 | 2023 | 43 | 2.360 |
Why?
|
| HIV Infections | 13 | 2022 | 253 | 1.950 |
Why?
|
| Sepsis | 3 | 2022 | 138 | 1.750 |
Why?
|
| Disaster Planning | 3 | 2021 | 29 | 1.680 |
Why?
|
| Critical Care | 5 | 2022 | 115 | 1.490 |
Why?
|
| Anti-Bacterial Agents | 9 | 2023 | 283 | 1.440 |
Why?
|
| Bacterial Infections | 2 | 2022 | 41 | 1.320 |
Why?
|
| Humans | 77 | 2023 | 28999 | 1.180 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 72 | 1.080 |
Why?
|
| Escherichia coli Infections | 9 | 2020 | 37 | 1.080 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 77 | 1.070 |
Why?
|
| Virus Diseases | 2 | 2022 | 18 | 0.990 |
Why?
|
| Clostridium Infections | 1 | 2023 | 9 | 0.970 |
Why?
|
| Leptospirosis | 4 | 2018 | 4 | 0.920 |
Why?
|
| Intensive Care Units | 3 | 2020 | 126 | 0.920 |
Why?
|
| Public Health | 2 | 2020 | 70 | 0.900 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2019 | 155 | 0.870 |
Why?
|
| Adult | 34 | 2023 | 8644 | 0.850 |
Why?
|
| Ficusin | 2 | 2011 | 5 | 0.810 |
Why?
|
| Dengue Virus | 2 | 2011 | 4 | 0.810 |
Why?
|
| Dengue Vaccines | 2 | 2011 | 3 | 0.810 |
Why?
|
| Travel | 4 | 2017 | 14 | 0.810 |
Why?
|
| Decision Making | 1 | 2022 | 189 | 0.810 |
Why?
|
| Diarrhea | 8 | 2020 | 56 | 0.800 |
Why?
|
| Resource Allocation | 1 | 2020 | 18 | 0.790 |
Why?
|
| Influenza, Human | 5 | 2020 | 119 | 0.770 |
Why?
|
| Triage | 1 | 2020 | 69 | 0.740 |
Why?
|
| Antigens, Bacterial | 4 | 2018 | 17 | 0.700 |
Why?
|
| Herpesvirus 3, Human | 2 | 2019 | 3 | 0.700 |
Why?
|
| Male | 41 | 2023 | 18231 | 0.690 |
Why?
|
| Biomedical Research | 1 | 2019 | 164 | 0.660 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2016 | 158 | 0.650 |
Why?
|
| Enterotoxigenic Escherichia coli | 6 | 2020 | 15 | 0.620 |
Why?
|
| Peru | 14 | 2020 | 18 | 0.620 |
Why?
|
| Military Medicine | 5 | 2020 | 25 | 0.620 |
Why?
|
| Mass Vaccination | 1 | 2016 | 7 | 0.620 |
Why?
|
| Reagins | 2 | 2013 | 2 | 0.600 |
Why?
|
| Leprosy, Multibacillary | 1 | 2015 | 1 | 0.570 |
Why?
|
| Influenza Vaccines | 1 | 2016 | 75 | 0.570 |
Why?
|
| Staphylococcal Infections | 2 | 2013 | 59 | 0.560 |
Why?
|
| Brucella melitensis | 3 | 2013 | 3 | 0.550 |
Why?
|
| Female | 35 | 2023 | 18453 | 0.550 |
Why?
|
| Neurocysticercosis | 1 | 2014 | 5 | 0.530 |
Why?
|
| Cerebral Ventricles | 1 | 2014 | 11 | 0.530 |
Why?
|
| United States | 19 | 2022 | 3700 | 0.530 |
Why?
|
| Disease Outbreaks | 6 | 2021 | 35 | 0.520 |
Why?
|
| Plasmodium vivax | 1 | 2013 | 1 | 0.510 |
Why?
|
| Malaria, Vivax | 1 | 2013 | 1 | 0.510 |
Why?
|
| Virus Shedding | 1 | 2013 | 3 | 0.510 |
Why?
|
| Daptomycin | 1 | 2013 | 3 | 0.510 |
Why?
|
| Chickenpox Vaccine | 1 | 2013 | 4 | 0.510 |
Why?
|
| Chickenpox | 1 | 2013 | 5 | 0.510 |
Why?
|
| Syphilis | 1 | 2013 | 5 | 0.510 |
Why?
|
| Nephritis | 1 | 2013 | 17 | 0.510 |
Why?
|
| Leptospira interrogans | 1 | 2013 | 1 | 0.510 |
Why?
|
| Fever of Unknown Origin | 1 | 2013 | 9 | 0.510 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2013 | 12 | 0.510 |
Why?
|
| Antibodies, Bacterial | 5 | 2019 | 28 | 0.500 |
Why?
|
| Young Adult | 13 | 2021 | 2409 | 0.490 |
Why?
|
| Fever | 1 | 2013 | 56 | 0.490 |
Why?
|
| Campylobacter Infections | 3 | 2020 | 6 | 0.480 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 428 | 0.470 |
Why?
|
| Middle Aged | 21 | 2020 | 11242 | 0.440 |
Why?
|
| Antiviral Agents | 3 | 2020 | 107 | 0.440 |
Why?
|
| Viral Load | 3 | 2020 | 54 | 0.430 |
Why?
|
| Bacteria, Anaerobic | 1 | 2011 | 3 | 0.430 |
Why?
|
| Peritoneal Diseases | 1 | 2011 | 4 | 0.430 |
Why?
|
| Biliary Tract Diseases | 1 | 2011 | 8 | 0.430 |
Why?
|
| Virus Inactivation | 1 | 2011 | 1 | 0.430 |
Why?
|
| Disinfectants | 1 | 2011 | 2 | 0.430 |
Why?
|
| Adenosine Monophosphate | 2 | 2020 | 6 | 0.420 |
Why?
|
| HIV-1 | 2 | 2022 | 41 | 0.410 |
Why?
|
| Alanine | 2 | 2020 | 26 | 0.410 |
Why?
|
| Culex | 1 | 2010 | 1 | 0.410 |
Why?
|
| Insect Bites and Stings | 1 | 2010 | 4 | 0.410 |
Why?
|
| Blister | 1 | 2010 | 7 | 0.410 |
Why?
|
| Critical Illness | 3 | 2022 | 85 | 0.410 |
Why?
|
| Severe Acute Respiratory Syndrome | 2 | 2020 | 9 | 0.400 |
Why?
|
| Escherichia coli Vaccines | 2 | 2020 | 10 | 0.390 |
Why?
|
| Antibodies, Viral | 3 | 2019 | 50 | 0.380 |
Why?
|
| Anti-HIV Agents | 2 | 2020 | 43 | 0.380 |
Why?
|
| Azithromycin | 4 | 2017 | 13 | 0.360 |
Why?
|
| Neurosyphilis | 1 | 2008 | 3 | 0.350 |
Why?
|
| Eye Diseases | 1 | 2008 | 7 | 0.350 |
Why?
|
| Fluoroquinolones | 2 | 2020 | 10 | 0.350 |
Why?
|
| Hemorrhagic Fever, Ebola | 2 | 2019 | 2 | 0.340 |
Why?
|
| Escherichia coli | 5 | 2017 | 78 | 0.340 |
Why?
|
| Respiration, Artificial | 4 | 2020 | 98 | 0.340 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2020 | 48 | 0.330 |
Why?
|
| Cholera Toxin | 2 | 2020 | 5 | 0.330 |
Why?
|
| Brucellosis | 3 | 2013 | 4 | 0.320 |
Why?
|
| Campylobacter jejuni | 2 | 2020 | 3 | 0.320 |
Why?
|
| Sentinel Surveillance | 3 | 2011 | 9 | 0.320 |
Why?
|
| Acute Disease | 3 | 2017 | 248 | 0.320 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2020 | 36 | 0.310 |
Why?
|
| Coccidioidomycosis | 2 | 2022 | 3 | 0.310 |
Why?
|
| Cohort Studies | 9 | 2023 | 1694 | 0.310 |
Why?
|
| Leptospira | 2 | 2018 | 2 | 0.310 |
Why?
|
| Viremia | 2 | 2019 | 5 | 0.300 |
Why?
|
| Treatment Outcome | 8 | 2020 | 3149 | 0.300 |
Why?
|
| Purines | 2 | 2020 | 16 | 0.290 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2020 | 39 | 0.290 |
Why?
|
| HIV | 3 | 2019 | 22 | 0.280 |
Why?
|
| Hospitalization | 4 | 2023 | 403 | 0.280 |
Why?
|
| Prospective Studies | 6 | 2022 | 1989 | 0.270 |
Why?
|
| Adolescent | 6 | 2020 | 3232 | 0.260 |
Why?
|
| Communicable Disease Control | 2 | 2016 | 12 | 0.250 |
Why?
|
| Surge Capacity | 2 | 2020 | 9 | 0.250 |
Why?
|
| Animals | 11 | 2020 | 7360 | 0.250 |
Why?
|
| Internationality | 2 | 2020 | 21 | 0.250 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2020 | 50 | 0.240 |
Why?
|
| Quality of Life | 2 | 2020 | 854 | 0.240 |
Why?
|
| Double-Blind Method | 5 | 2020 | 521 | 0.240 |
Why?
|
| Case-Control Studies | 6 | 2022 | 927 | 0.240 |
Why?
|
| Anthrax | 1 | 2022 | 5 | 0.240 |
Why?
|
| Bacillus anthracis | 1 | 2022 | 9 | 0.240 |
Why?
|
| Antitoxins | 1 | 2022 | 6 | 0.240 |
Why?
|
| Risk-Taking | 2 | 2020 | 88 | 0.230 |
Why?
|
| HIV Seropositivity | 1 | 2021 | 11 | 0.220 |
Why?
|
| Immunoglobulin G | 4 | 2019 | 101 | 0.220 |
Why?
|
| Pericarditis | 3 | 2013 | 6 | 0.220 |
Why?
|
| Afghanistan | 2 | 2017 | 5 | 0.210 |
Why?
|
| RNA, Viral | 1 | 2021 | 53 | 0.210 |
Why?
|
| Naval Medicine | 1 | 2021 | 1 | 0.210 |
Why?
|
| Time Factors | 4 | 2020 | 2030 | 0.210 |
Why?
|
| Azetidines | 1 | 2020 | 9 | 0.210 |
Why?
|
| Adhesins, Escherichia coli | 1 | 2020 | 3 | 0.210 |
Why?
|
| Ventilators, Mechanical | 1 | 2020 | 6 | 0.210 |
Why?
|
| Hospitals, Military | 2 | 2020 | 7 | 0.210 |
Why?
|
| Alum Compounds | 2 | 2011 | 4 | 0.200 |
Why?
|
| DNA Gyrase | 1 | 2020 | 1 | 0.200 |
Why?
|
| Medical Staff, Hospital | 1 | 2020 | 17 | 0.200 |
Why?
|
| Antibodies, Neutralizing | 2 | 2011 | 17 | 0.200 |
Why?
|
| Point Mutation | 1 | 2020 | 18 | 0.200 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2020 | 29 | 0.200 |
Why?
|
| Drug Industry | 1 | 2020 | 16 | 0.200 |
Why?
|
| Pyrazoles | 1 | 2020 | 63 | 0.200 |
Why?
|
| Sulfonamides | 1 | 2020 | 67 | 0.200 |
Why?
|
| California | 2 | 2022 | 61 | 0.200 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 27 | 0.200 |
Why?
|
| Sexual Behavior | 1 | 2020 | 75 | 0.200 |
Why?
|
| Adjuvants, Immunologic | 2 | 2011 | 52 | 0.190 |
Why?
|
| Immunization, Passive | 1 | 2019 | 3 | 0.190 |
Why?
|
| Photorefractive Keratectomy | 1 | 2019 | 3 | 0.190 |
Why?
|
| Myopia | 1 | 2019 | 5 | 0.190 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 60 | 0.190 |
Why?
|
| Patient Care Team | 1 | 2021 | 122 | 0.190 |
Why?
|
| Lasers, Excimer | 1 | 2019 | 8 | 0.190 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 48 | 0.190 |
Why?
|
| Plasma | 1 | 2019 | 16 | 0.190 |
Why?
|
| Homosexuality, Male | 1 | 2020 | 65 | 0.190 |
Why?
|
| Cornea | 1 | 2019 | 12 | 0.190 |
Why?
|
| Melioidosis | 1 | 2019 | 2 | 0.190 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 62 | 0.190 |
Why?
|
| Measles | 1 | 2019 | 2 | 0.190 |
Why?
|
| Influenza A virus | 1 | 2019 | 21 | 0.190 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2020 | 32 | 0.190 |
Why?
|
| Herpes Zoster | 1 | 2019 | 10 | 0.190 |
Why?
|
| Gastroenteritis | 2 | 2017 | 12 | 0.190 |
Why?
|
| Emergencies | 1 | 2019 | 48 | 0.190 |
Why?
|
| Child | 5 | 2020 | 2130 | 0.190 |
Why?
|
| Ciprofloxacin | 3 | 2020 | 12 | 0.180 |
Why?
|
| Health Policy | 1 | 2019 | 73 | 0.180 |
Why?
|
| Immunoglobulin M | 3 | 2018 | 16 | 0.180 |
Why?
|
| Angiostrongylus cantonensis | 1 | 2018 | 1 | 0.180 |
Why?
|
| Strongylida Infections | 1 | 2018 | 2 | 0.180 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2019 | 39 | 0.180 |
Why?
|
| Zoonoses | 1 | 2018 | 3 | 0.180 |
Why?
|
| Serologic Tests | 1 | 2018 | 9 | 0.180 |
Why?
|
| Central Nervous System Diseases | 1 | 2018 | 12 | 0.180 |
Why?
|
| Respiratory Tract Infections | 1 | 2018 | 40 | 0.170 |
Why?
|
| Mental Disorders | 1 | 2019 | 99 | 0.170 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 413 | 0.170 |
Why?
|
| Aged | 9 | 2020 | 9677 | 0.170 |
Why?
|
| Incidence | 5 | 2022 | 1097 | 0.170 |
Why?
|
| Emergency Medical Services | 1 | 2020 | 153 | 0.170 |
Why?
|
| Ships | 2 | 2021 | 2 | 0.160 |
Why?
|
| Polymerase Chain Reaction | 3 | 2012 | 167 | 0.160 |
Why?
|
| Travel Medicine | 1 | 2017 | 1 | 0.160 |
Why?
|
| Aotidae | 2 | 2020 | 2 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 966 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 381 | 0.150 |
Why?
|
| Escherichia coli Proteins | 3 | 2011 | 26 | 0.150 |
Why?
|
| Alcohol Drinking | 1 | 2019 | 230 | 0.150 |
Why?
|
| Prognosis | 1 | 2020 | 1384 | 0.150 |
Why?
|
| DNA, Bacterial | 3 | 2012 | 17 | 0.150 |
Why?
|
| Norovirus | 2 | 2017 | 3 | 0.150 |
Why?
|
| Mycobacterium leprae | 1 | 2015 | 1 | 0.140 |
Why?
|
| Bacterial Typing Techniques | 2 | 2012 | 9 | 0.140 |
Why?
|
| Neoplasms | 1 | 2022 | 644 | 0.140 |
Why?
|
| Health Personnel | 1 | 2016 | 107 | 0.140 |
Why?
|
| Communicable Diseases, Emerging | 2 | 2011 | 2 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2016 | 465 | 0.130 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 65 | 0.130 |
Why?
|
| Shiga-Toxigenic Escherichia coli | 2 | 2011 | 3 | 0.130 |
Why?
|
| Infant | 5 | 2018 | 936 | 0.130 |
Why?
|
| Risk Factors | 5 | 2019 | 3569 | 0.130 |
Why?
|
| Biopsy | 1 | 2015 | 240 | 0.130 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2013 | 3 | 0.130 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2013 | 3 | 0.130 |
Why?
|
| Soft Tissue Infections | 1 | 2013 | 10 | 0.130 |
Why?
|
| False Positive Reactions | 1 | 2013 | 23 | 0.130 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 285 | 0.130 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 25 | 0.130 |
Why?
|
| Child, Preschool | 5 | 2018 | 1156 | 0.120 |
Why?
|
| Vaccination | 2 | 2013 | 100 | 0.120 |
Why?
|
| Demography | 1 | 2013 | 113 | 0.120 |
Why?
|
| Lactoferrin | 1 | 2013 | 2 | 0.120 |
Why?
|
| Gangliosides | 1 | 2013 | 6 | 0.120 |
Why?
|
| Foodborne Diseases | 1 | 2013 | 2 | 0.120 |
Why?
|
| Skin | 1 | 2015 | 205 | 0.120 |
Why?
|
| Severity of Illness Index | 3 | 2022 | 890 | 0.120 |
Why?
|
| Myocarditis | 1 | 2013 | 5 | 0.120 |
Why?
|
| Campylobacter coli | 1 | 2012 | 2 | 0.120 |
Why?
|
| Intestinal Mucosa | 1 | 2013 | 63 | 0.120 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2012 | 6 | 0.120 |
Why?
|
| Shigella | 1 | 2012 | 7 | 0.120 |
Why?
|
| Mice | 3 | 2020 | 2331 | 0.120 |
Why?
|
| Hemoptysis | 1 | 2011 | 3 | 0.110 |
Why?
|
| Caliciviridae Infections | 1 | 2011 | 2 | 0.110 |
Why?
|
| Drug Resistance, Microbial | 1 | 2011 | 10 | 0.110 |
Why?
|
| Dengue | 1 | 2011 | 4 | 0.110 |
Why?
|
| Immunization, Secondary | 1 | 2011 | 9 | 0.110 |
Why?
|
| Gentamicins | 1 | 2011 | 4 | 0.110 |
Why?
|
| Comorbidity | 3 | 2020 | 557 | 0.110 |
Why?
|
| Rifampin | 1 | 2011 | 7 | 0.110 |
Why?
|
| Vibrio parahaemolyticus | 1 | 2010 | 1 | 0.100 |
Why?
|
| Aeromonas hydrophila | 1 | 2010 | 1 | 0.100 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2020 | 7 | 0.100 |
Why?
|
| Doxycycline | 1 | 2011 | 24 | 0.100 |
Why?
|
| Fimbriae Proteins | 1 | 2010 | 5 | 0.100 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 45 | 0.100 |
Why?
|
| Food Handling | 1 | 2010 | 6 | 0.100 |
Why?
|
| Seafood | 1 | 2010 | 11 | 0.100 |
Why?
|
| Respiratory Tract Diseases | 1 | 2011 | 36 | 0.100 |
Why?
|
| South America | 1 | 2010 | 3 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 1 | 2011 | 42 | 0.100 |
Why?
|
| Phenotype | 2 | 2023 | 664 | 0.100 |
Why?
|
| Australia | 2 | 2021 | 29 | 0.100 |
Why?
|
| Fruit | 1 | 2010 | 57 | 0.100 |
Why?
|
| Injections, Intradermal | 1 | 2009 | 6 | 0.100 |
Why?
|
| Vaccines, Inactivated | 1 | 2009 | 36 | 0.100 |
Why?
|
| Hospital Mortality | 2 | 2020 | 190 | 0.090 |
Why?
|
| Cardiolipins | 1 | 2008 | 2 | 0.090 |
Why?
|
| Phosphatidylcholines | 1 | 2008 | 21 | 0.090 |
Why?
|
| Cerebrospinal Fluid | 1 | 2008 | 13 | 0.090 |
Why?
|
| Sulfones | 1 | 2008 | 14 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 1210 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 220 | 0.090 |
Why?
|
| Piperazines | 1 | 2008 | 56 | 0.090 |
Why?
|
| Honduras | 1 | 2017 | 1 | 0.090 |
Why?
|
| Loperamide | 1 | 2017 | 1 | 0.090 |
Why?
|
| Djibouti | 1 | 2017 | 1 | 0.090 |
Why?
|
| Kenya | 1 | 2017 | 6 | 0.090 |
Why?
|
| Retrospective Studies | 4 | 2022 | 3073 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 524 | 0.080 |
Why?
|
| Aneurysm, Infected | 1 | 2006 | 4 | 0.080 |
Why?
|
| Cholesterol | 1 | 2008 | 236 | 0.080 |
Why?
|
| Methicillin Resistance | 1 | 2006 | 12 | 0.080 |
Why?
|
| Aneurysm, False | 1 | 2006 | 13 | 0.080 |
Why?
|
| Community-Acquired Infections | 1 | 2006 | 31 | 0.080 |
Why?
|
| Staphylococcus aureus | 1 | 2006 | 44 | 0.080 |
Why?
|
| Feces | 2 | 2019 | 29 | 0.070 |
Why?
|
| Aorta | 1 | 2006 | 113 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2018 | 246 | 0.070 |
Why?
|
| Prevalence | 3 | 2012 | 912 | 0.070 |
Why?
|
| Infection Control | 2 | 2016 | 20 | 0.060 |
Why?
|
| Age Factors | 2 | 2018 | 1129 | 0.060 |
Why?
|
| Convalescence | 1 | 2022 | 2 | 0.060 |
Why?
|
| Bacillus cereus | 1 | 2022 | 1 | 0.060 |
Why?
|
| Coccidioides | 1 | 2022 | 1 | 0.060 |
Why?
|
| Plasmids | 1 | 2022 | 46 | 0.060 |
Why?
|
| Enterotoxins | 2 | 2013 | 6 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2023 | 227 | 0.060 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 2 | 2012 | 6 | 0.060 |
Why?
|
| Serotyping | 2 | 2012 | 14 | 0.060 |
Why?
|
| Goats | 2 | 2013 | 4 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2021 | 49 | 0.050 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 2001 | 2 | 0.050 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2001 | 4 | 0.050 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2001 | 3 | 0.050 |
Why?
|
| Hypertension, Portal | 1 | 2001 | 10 | 0.050 |
Why?
|
| Unsafe Sex | 1 | 2020 | 15 | 0.050 |
Why?
|
| Guinea Pigs | 1 | 2020 | 12 | 0.050 |
Why?
|
| Virulence Factors | 2 | 2011 | 7 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2001 | 19 | 0.050 |
Why?
|
| Patient Care | 1 | 2021 | 35 | 0.050 |
Why?
|
| Inventories, Hospital | 1 | 2020 | 1 | 0.050 |
Why?
|
| Ritonavir | 1 | 2020 | 2 | 0.050 |
Why?
|
| Isoleucine | 1 | 2020 | 6 | 0.050 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 24 | 0.050 |
Why?
|
| Disasters | 1 | 2020 | 11 | 0.050 |
Why?
|
| Threonine | 1 | 2020 | 12 | 0.050 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 10 | 0.050 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2020 | 22 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2020 | 79 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 37 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 1 | 2020 | 30 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 69 | 0.050 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 53 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 43 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2020 | 83 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2001 | 82 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2020 | 15 | 0.050 |
Why?
|
| CD4-CD8 Ratio | 1 | 2020 | 2 | 0.050 |
Why?
|
| Seasons | 1 | 2020 | 96 | 0.050 |
Why?
|
| Natural History | 1 | 2019 | 1 | 0.050 |
Why?
|
| Neuropsychological Tests | 1 | 2021 | 388 | 0.050 |
Why?
|
| Measles Vaccine | 1 | 2019 | 1 | 0.050 |
Why?
|
| Burkholderia pseudomallei | 1 | 2019 | 1 | 0.050 |
Why?
|
| History, 21st Century | 1 | 2019 | 50 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2019 | 72 | 0.050 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2019 | 4 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2021 | 282 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2019 | 163 | 0.050 |
Why?
|
| Visual Acuity | 1 | 2019 | 67 | 0.050 |
Why?
|
| Administration, Intranasal | 1 | 2019 | 30 | 0.050 |
Why?
|
| Length of Stay | 1 | 2020 | 296 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2019 | 137 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 190 | 0.040 |
Why?
|
| Primates | 1 | 2019 | 99 | 0.040 |
Why?
|
| Mass Screening | 1 | 2020 | 206 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2019 | 308 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 730 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2018 | 63 | 0.040 |
Why?
|
| Continental Population Groups | 1 | 2019 | 233 | 0.040 |
Why?
|
| Campylobacter | 1 | 2017 | 2 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 667 | 0.040 |
Why?
|
| Sex Factors | 1 | 2018 | 652 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 722 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2016 | 89 | 0.040 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 2015 | 1 | 0.040 |
Why?
|
| Rivers | 1 | 2015 | 2 | 0.040 |
Why?
|
| Parasitic Diseases | 1 | 2015 | 5 | 0.040 |
Why?
|
| Child Nutrition Disorders | 1 | 2015 | 4 | 0.040 |
Why?
|
| Malaria | 1 | 2015 | 9 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 1018 | 0.030 |
Why?
|
| Agglutination Tests | 1 | 2013 | 2 | 0.030 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2013 | 5 | 0.030 |
Why?
|
| Species Specificity | 1 | 2013 | 81 | 0.030 |
Why?
|
| G(M1) Ganglioside | 1 | 2013 | 1 | 0.030 |
Why?
|
| Lipoproteins | 1 | 2013 | 81 | 0.030 |
Why?
|
| Chlorides | 1 | 2013 | 15 | 0.030 |
Why?
|
| Ferric Compounds | 1 | 2013 | 14 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2013 | 69 | 0.030 |
Why?
|
| Cheese | 1 | 2013 | 1 | 0.030 |
Why?
|
| Food Microbiology | 1 | 2013 | 1 | 0.030 |
Why?
|
| Contact Tracing | 1 | 2013 | 5 | 0.030 |
Why?
|
| Smallpox Vaccine | 1 | 2013 | 2 | 0.030 |
Why?
|
| Cattle | 1 | 2013 | 92 | 0.030 |
Why?
|
| Police | 1 | 2013 | 22 | 0.030 |
Why?
|
| Intestines | 1 | 2013 | 52 | 0.030 |
Why?
|
| Rural Population | 1 | 2015 | 290 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2013 | 70 | 0.030 |
Why?
|
| Protein Binding | 1 | 2013 | 185 | 0.030 |
Why?
|
| Erythromycin | 1 | 2012 | 6 | 0.030 |
Why?
|
| Health Status | 1 | 2015 | 381 | 0.030 |
Why?
|
| DNA, Intergenic | 1 | 2012 | 9 | 0.030 |
Why?
|
| Dysentery, Bacillary | 1 | 2012 | 13 | 0.030 |
Why?
|
| Hawaii | 1 | 2011 | 3 | 0.030 |
Why?
|
| Syndrome | 1 | 2011 | 67 | 0.030 |
Why?
|
| Hemolysin Proteins | 1 | 2011 | 1 | 0.030 |
Why?
|
| Adhesins, Bacterial | 1 | 2011 | 2 | 0.030 |
Why?
|
| Laboratories | 1 | 2011 | 13 | 0.030 |
Why?
|
| Shiga Toxin | 1 | 2011 | 2 | 0.030 |
Why?
|
| Genes, Bacterial | 1 | 2011 | 7 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 650 | 0.030 |
Why?
|
| Phylogeny | 1 | 2011 | 52 | 0.030 |
Why?
|
| Microbial Viability | 1 | 2010 | 4 | 0.030 |
Why?
|
| Communicable Diseases | 1 | 2011 | 19 | 0.030 |
Why?
|
| Enteropathogenic Escherichia coli | 1 | 2010 | 3 | 0.030 |
Why?
|
| Bacterial Adhesion | 1 | 2010 | 7 | 0.030 |
Why?
|
| Nutritional Sciences | 1 | 2010 | 10 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2010 | 17 | 0.030 |
Why?
|
| Beverages | 1 | 2010 | 20 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2010 | 66 | 0.030 |
Why?
|
| Vegetables | 1 | 2010 | 39 | 0.030 |
Why?
|
| Bacterial Toxins | 1 | 2010 | 16 | 0.030 |
Why?
|
| Base Sequence | 1 | 2011 | 226 | 0.030 |
Why?
|
| Forecasting | 1 | 2011 | 134 | 0.020 |
Why?
|
| DNA Fingerprinting | 1 | 2009 | 7 | 0.020 |
Why?
|
| Minisatellite Repeats | 1 | 2009 | 10 | 0.020 |
Why?
|
| Dairy Products | 1 | 2009 | 12 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2009 | 21 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 2013 | 285 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2009 | 123 | 0.020 |
Why?
|
| Hospitals | 1 | 2009 | 75 | 0.020 |
Why?
|
| Urban Population | 1 | 2009 | 79 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2011 | 575 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 827 | 0.020 |
Why?
|
| Empyema, Pleural | 1 | 2006 | 6 | 0.020 |
Why?
|
| Peritonitis | 1 | 2006 | 10 | 0.020 |
Why?
|
| Pharyngeal Diseases | 1 | 2006 | 7 | 0.020 |
Why?
|
| Buttocks | 1 | 2006 | 5 | 0.020 |
Why?
|
| Myositis | 1 | 2006 | 10 | 0.020 |
Why?
|
| Abscess | 1 | 2006 | 26 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2006 | 33 | 0.020 |
Why?
|
| Tracheostomy | 1 | 2006 | 27 | 0.020 |
Why?
|
| Radiography | 1 | 2006 | 348 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2001 | 88 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2001 | 1319 | 0.010 |
Why?
|